drugset
drugset / Trial / NCT06778863

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

NCT06778863 ↗

Phase 1 Recruiting 90 enrolled Clasp Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

Timeline

Start
2025-02-28
Primary completion
2027-12
Completion
2028-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CLSP-1025 Other / unclassified — Intravenous

Indications

breast cancer colorectal adenocarcinoma head and neck squamous cell carcinoma lung cancer metastatic neoplasm ovarian cancer pancreatic adenocarcinoma prostate cancer urinary bladder cancer